Local therapeutic efficacy with reduced systemic side effects by rapamycin-loaded subcapsular microspheres

Biomaterials

Volumn 42, Issue , 2015, Pages 151-160

  Falke, Lucas L ^a   van Vuuren, Stefan H ^a   Kazazi Hyseni, Filis ^b   Ramazani, Farshad ^b   Nguyen, Tri Q ^a   Veldhuis, Gert J ^c   Maarseveen, Erik M ^a   Zandstra, Jurjen ^d   Zuidema, Johan ^e   Duque, Luisa F ^e   Steendam, Rob ^e   Popa, Eliane R ^d   Kok, Robbert Jan ^b   Goldschmeding, Roel ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NANOMI B V   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e InnoCore Pharmaceuticals   (Netherlands)

Author keywords

Chronic kidney disease; Fibrosis; Microsphere; MTOR; Rapamycin; Subcapsular delivery

Indexed keywords

ANTIBIOTICS; T-CELLS;

CHRONIC KIDNEY DISEASE; FIBROSIS; MTOR; RAPAMYCIN; SUBCAPSULAR DELIVERY;

MICROSPHERES;

ALPHA SMOOTH MUSCLE ACTIN; CD3 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MICROSPHERE; PLACEBO; PROTEIN S6; RAPAMYCIN; ANTIINFLAMMATORY AGENT; MICROCAPSULE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOACCUMULATION; BODY WEIGHT; CD3+ T LYMPHOCYTE; CELL INFILTRATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEGRADATION KINETICS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TISSUE LEVEL; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; INCUBATION TEMPERATURE; KIDNEY CAPSULE; KIDNEY DISEASE; LIMIT OF DETECTION; LOCAL THERAPY; MYOFIBROBLAST; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; POSTOPERATIVE COMPLICATION; RAT; SYSTEMIC THERAPY; THERAPY EFFECT; TREATMENT RESPONSE; URETER OBSTRUCTION; WEIGHT REDUCTION; ANIMAL; DRUG EFFECTS; FIBROSIS; FISCHER 344 RAT; GENE EXPRESSION REGULATION; KIDNEY; METABOLISM; MICROCAPSULE; PATHOLOGY; SCANNING ELECTRON MICROSCOPY; T LYMPHOCYTE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; URETERAL OBSTRUCTION;

RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CAPSULES; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION; KIDNEY; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; MYOFIBROBLASTS; RATS, INBRED F344; SIROLIMUS; T-LYMPHOCYTES; TISSUE DISTRIBUTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; URETERAL OBSTRUCTION;

EID: 84919627533     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.11.042     Document Type: Article

References (41)

1. Takada M., Nadeau K.C., Shaw G.D., Marquette K.A., Tilney N.L. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 1997, 99:2682-2690.
2. Friedewald J.J., Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004, 66:486-491.
3. Ysebaert D.K., De Greef K.E., Vercauteren S.R., Ghielli M., Verpooten G.A., Eyskens E.J., et al. Identification and kinetics of leukocytes after severe ischaemia/reperfusion renal injury. Nephrol Dial Transpl 2000, 15:1562-1574.
4. Donnahoo K.K., Meng X., Ayala A., Cain M.P., Harken A.H., Meldrum D.R. Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol 1999, 277:R922-R929.
5. Togel F., Westenfelder C. Recent advances in the understanding of acute kidney injury. F1000Prime Rep 2014, 6:83.
6. Rui L. A link between protein translation and body weight. J Clin Invest 2007, 117:310-313.
7. Bonegio R.G., Fuhro R., Wang Z., Valeri C.R., Andry C., Salant D.J., et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005, 16:2063-2072.
8. Huber T.B., Walz G., Kuehn E.W. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011, 79:502-511.
9. Kramer S., Wang-Rosenke Y., Scholl V., Binder E., Loof T., Khadzhynov D., et al. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Ren Physiol 2008, 294:F440-F449.
10. Lieberthal W., Levine J.S. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009, 20:2493-2502.
11. Lock H.R., Sacks S.H., Robson M.G. Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production. Am J Physiol Ren Physiol 2007, 292:F76-F81.
12. Schaefer L., Tsalastra W., Babelova A., Baliova M., Minnerup J., Sorokin L., et al. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin. Am J Pathol 2007, 170:301-315.
13. Wu M.J., Wen M.C., Chiu Y.T., Chiou Y.Y., Shu K.H., Tang M.J. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006, 69:2029-2036.
14. Cruzado J.M. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant Rev (Orlando) 2008, 22:73-81.
15. Jiang L., Xu L., Mao J., Li J., Fang L., Zhou Y., et al. Rheb/mTORC1 signaling promotes kidney fibroblast activation and fibrosis. J Am Soc Nephrol 2013, 24:1114-1126.
16. Chen G., Chen H., Wang C., Peng Y., Sun L., Liu H., et al. Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One 2012, 7:e33626.
17. Gonzalez J., Harris T., Childs G., Prystowsky M.B. Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival. Blood Cells Mol Dis 2001, 27:572-585.
18. Rostaing L., Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?. J Nephrol 2010, 23:133-142.
19. Deblon N., Bourgoin L., Veyrat-Durebex C., Peyrou M., Vinciguerra M., Caillon A., et al. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol 2012, 165:2325-2340.
20. Leeuwis J.W., Nguyen T.Q., Dendooven A., Kok R.J., Goldschmeding R. Targeting podocyte-associated diseases. Adv Drug Deliv Rev 2010, 62:1325-1336.
21. Dolman M.E., Harmsen S., Storm G., Hennink W.E., Kok R.J. Drug targeting to the kidney: advances in the active targeting of therapeutics to proximal tubular cells. Adv Drug Deliv Rev 2010, 62:1344-1357.
22. Shillingford J.M., Leamon C.P., Vlahov I.R., Weimbs T. Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol 2012, 23:1674-1681.
23. Stokman G., Qin Y., Racz Z., Hamar P., Price L.S. Application of siRNA in targeting protein expression in kidney disease. Adv Drug Deliv Rev 2010, 62:1378-1389.
24. Khan W., Farah S., Domb A.J. Drug eluting stents: developments and current status. J Control Release 2012, 161:703-712.
25. Jelonek K., Kasperczyk J., Li S., Dobrzynski P., Jarzabek B. Controlled poly(l-lactide-co-trimethylene carbonate) delivery system of cyclosporine A and rapamycine-the effect of copolymer chain microstructure on drug release rate. Int J Pharm 2011, 414:203-209.
26. Filova E., Parizek M., Olsovska J., Kamenik Z., Brynda E., Riedel T., et al. Perivascular sirolimus-delivery system. Int J Pharm 2011, 404:94-101.
27. Owen S.C., Li H., Sanders W.G., Cheung A.K., Terry C.M. Correlation of tissue drug concentrations with in vivo magnetic resonance images of polymer drug depot around arteriovenous graft. J Control Release 2010, 146:23-30.
28. Dankers P.Y., van Luyn M.J., Huizinga-van der Vlag A., van Gemert G.M., Petersen A.H., Meijer E.W., et al. Development and in-vivo characterization of supramolecular hydrogels for intrarenal drug delivery. Biomaterials 2012, 33:5144-5155.
29. Dankers P.Y., Hermans T.M., Baughman T.W., Kamikawa Y., Kieltyka R.E., Bastings M.M., et al. Hierarchical formation of supramolecular transient networks in water: a modular injectable delivery system. Adv Mater 2012, 24:2703-2709.
30. Merani S., Toso C., Emamaullee J., Shapiro A.M. Optimal implantation site for pancreatic islet transplantation. Br J Surg 2008, 95:1449-1461.
31. Cole D.R., Waterfall M., McIntyre M., Baird J.D. Transplantation of microcapsules (a potential bio-artificial organ): biocompatibility and host reaction. J Mater Sci Mater Med 1993, 4:437-442.
32. Lanza R.P., Kuhtreiber W.M., Ecker D., Staruk J.E., Chick W.L. Xenotransplantation of porcine and bovine islets without immunosuppression using uncoated alginate microspheres. Transplantation 1995, 59:1377-1384.
33. Lockwood N.A., Hergenrother R.W., Patrick L.M., Stucke S.M., Steendam R., Pacheco E., et al. In vitro and in vivo characterization of novel biodegradable polymers for application as drug-eluting stent coatings. J Biomater Sci Polym Ed 2010, 21:529-552.
34. Jhunjhunwala S., Raimondi G., Thomson A.W., Little S.R. Delivery of rapamycin to dendritic cells using degradable microparticles. J Control Release 2009, 133:191-197.
35. Kauffman K.J., Kanthamneni N., Meenach S.A., Pierson B.C., Bachelder E.M., Ainslie K.M. Optimization of rapamycin-loaded acetalated dextran microparticles for immunosuppression. Int J Pharm 2012, 422:356-363.
36. Lewis J.S., Roche C., Zhang Y., Brusko T.M., Wasserfall C.H., Atkinson M., et al. Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres. J Mater Chem B Mater Biol Med 2014, 2:2562-2574.
37. Gupta A., Pant G., Mitra K., Madan J., Chourasia M.K., Misra A. Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis. Mol Pharm 2014, 11:1201-1207.
38. Kazazi-Hyseni F., Landin M., Lathuile A., Veldhuis G.J., Rahimian S., Hennink W.E., et al. Computer modeling assisted design of monodisperse PLGA microspheres with controlled porosity affords zero order release of an encapsulated macromolecule for 3 months. Pharm Res 2014, 31:2844-2856.
39. Koster R.A., Dijkers E.C., Uges D.R. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood. Ther Drug Monit 2009, 31:116-125.
40. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011, 7:684-696.
41. Zandstra J., Hiemstra C., Petersen A.H., Zuidema J., van Beuge M.M., Rodriguez S., et al. Microsphere size influences the foreign body reaction. Eur Cell Mater 2014, 28:335-347.